Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/07/2008
Trade Name:
Orencia
Generic Name or Proper Name (*):
abatacept
Indications Studied:
Moderate to severe polyarticular juvenile idiopathic arthritis
Label Changes Summary:
Indicated for reducing signs and symptoms in pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) ages 6 years and older. The safety and effectiveness in pediatric patients < 6 years of age and in pediatric patients for uses other than JIA have not been established Abatacept was studied in 190 patients 6 - 17 years with polyarticular JIA. AEs were generally similar to those seen in adults. Overall frequency of adverse events in the 4-month, lead-in, open-label period of the study was 70%; infections occurred at a frequency of 36%. A total of 6 serious adverse events were reported during the initial 4 months of treatment with abatacept. Information on dosing, PK, immunogenicity, immunization needs, AEs, and clinical study New indication
PREA(P):
P
Sponsor:
Bristol-Myers Squibb
NNPS:
FALSE'
Therapeutic Category:
Anti-inflammatory
-
-